The Market is a key contributor to global growth, supported by advanced healthcare facilities and strong adoption of minimally invasive treatments. Continuous innovation in neurovascular devices and rising diagnosis rates are further driving market expansion.
An intracranial aneurysm is a bulging or weakened area in a blood vessel inside the brain that can swell due to high blood pressure. It is ruptures, which may lead to serious, life-threatening violence. The U.S. intracranial aneurysm market is growing due to the rising prevalence of hypertension, stroke, and age-related cerebrovascular disorders. Strong healthcare infrastructure, early diagnosis through advanced imaging technologies, and increasing adoption of minimally invasive treatments such as flow diversion are further driving demand. Continuous innovation by leading medical device companies is also supporting sustained market expansion.
The global intracranial aneurysm market size was estimated at USD 2.45 billion in 2025 and is predicted to increase from USD 2.66 billion in 2026 to approximately USD 5.64 billion by 2035, expanding at a CAGR of 8.7% from 2026 to 2035.
The U.S. intracranial aneurysm market is expected to grow strongly due to the use of minimally invasive neurovascular procedures, increasing adoption of AI-based imaging for early detection, and continuous innovation in low-diversity and embolization devices. Growing neurological disease burden and improved healthcare infrastructure, especially economies, will further support long-term market expansion and better patient outcomes.
| Year | Patients | Deaths |
| 2023 | 1.30 billion | 10 million |
| 2024 | 1.35 billion | 10.5 million |
| 2025 | 1.40 billion | 11 million |
The global hypertension burden is steadily rising from 2023 to 2025 due to increasing risk factors such as unhealthy diets, obesity, stress, and an aging population. Growing awareness and improved diagnosis are also increasing reported cases. This rising burden significantly contributes to cardiovascular complications, leading to higher mortality rates worldwide.
The aneurysm segment dominated the U.S. intracranial aneurysm market with a share of 68% in 2025 due to its high prevalence as the most commonly diagnosed intracranial aneurysm type. Its characteristic sac-like structure makes it easier to detect through advanced imaging, leading to higher diagnosis rates. Strong clinical preference for minimally invasive treatments like coiling and flow diversion, along with well-established treatment protocols, further contributed to its leading market position.
The endovascular coiling segment led the U.S. intracranial aneurysm market with a 68% share in 2025 due to its widespread adoption as a minimally invasive treatment option. It provides faster recovery, reduced surgical complications, and shorter hospital stays compared to open surgical clipping. Strong clinical success rates, advanced coil technologies, and high availability of skilled neurointerventional specialists in the U.S. further strengthened its dominant market position.
The hospitals segment held a dominant share of 72% in 2025 due to their ability to handle high volumes of intracranial aneurysm cases, including emergencies such as re-ruptures. Hospitals are equipped with advanced neuroimaging systems, skilled neurosurgeons, and intensive care units, enabling comprehensive diagnosis and treatment. Their strong infrastructure, 24/7 availability, and preference for complex neurovascular procedures further support their leading market position.
The digital subtraction angiography (DSA) segment led the U.S. intracranial aneurysm market with 36% share in 2025 due to its status as the gold standard for detecting intracranial aneurysms. It provides a highly detailed, real-time visualization of cerebral blood vessels, enabling precise localization, size assessment, and treatment planning. Its superior diagnostic accuracy, widespread use in hospitals, and importance in guiding neurointerventional procedures contributed to its dominant market position.
Leading companies in the market include Stryker Corporation, Medtronic, Johnson & Johnson (Cerenovus), Terumo Corporation, Penumbra, Inc., MicroPort Scientific Corporation, Boston Scientific, Siemens Healthineers, Philips Healthcare, GE HealthCare, and B. Braun Melsungen. These companies dominate through strong portfolios of flow diverters, embolization coils, stent systems, and advanced neuroimaging and neurovascular solutions, driving innovation in minimally invasive aneurysm treatment and diagnostics.
By Type
By Treatment Type
By End User
By Diagnosis Modality
